The IndiPharm Newswire
IndiPharm’s Nigel McBean appointed to new DIA Provisional Advisory Council of India - Council to provide strategic advice to DIA
RADNOR, PA, October 25 — IndiPharm, Inc. today announced the appointment of Nigel McBean to the new DIA Provisional Advisory Council of India. This Council will provide strategic advice to the DIA on opportunities which serve the biopharmaceutical community, oversee the portfolio of products and services offered in India, and play a vital role in identifying industry trends and issues so that DIA can position itself best to serve its global constituents.
Mr. McBean, Vice President and Director of Operations, IndiPharm (India) Pvt. Ltd., a wholly owned subsidiary of IndiPharm, Inc, is one of 30 leaders of India’s pharmaceutical, life sciences, and healthcare industries to be chosen for this important assignment. Mr. McBean has more than 18 years of experience conducting and managing clinical trials across Asia with various multinational pharmaceutical companies and global contract research organizations (CROs). He brings extensive knowledge and experience regarding clinical trials in India.
"I am honored to be selected to serve on this new and important Council. Based upon my background and experience, I will be able to contribute actively to identifying key issues and providing strategic advice to the DIA." said Nigel McBean, Vice President and Director of Operations, IndiPharm (India) Pvt. Ltd.
About DIA (Drug Information Association)
DIA is a volunteer-driven, non-profit association that serves professionals worldwide in the multiple disciplines that comprise the contemporary biopharmaceutical industry. DIA is committed to improving quality and enhancing innovation by offering relevant information in a neutral, global environment. DIA coordinates its services from offices in the United States, Switzerland, Japan, India, and China. Its office in Mumbai, India is under the leadership of Director, Sultan Ghani who works closely in collaboration with the DIA Provisional Advisory Council of India toward the goal of providing a world-class presence in India.
About IndiPharm
IndiPharm is a U.S. based full service clinical research organization (CRO) providing Western pharmaceutical and biotechnology companies a full range of clinical trial services through its wholly owned subsidiary – IndiPharm (India) Pvt. Ltd. and its network of qualified physicians and scientists located in India, enabling those companies to conduct registration quality Phase I through IV clinical trials quicker and at a lower cost than is generally possible in the United States and other Western countries.
For more information, contact:
Michael Brown
Vice President, Business Development
IndiPharm, Inc
610-230-0153
mbrown@indipharm.com